Kizilors et al. screened for low-level BCR::ABL1 mutations in consecutive newly diagnosed CML patients, including both optimal responders and those resistant to TKIs [38]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.